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ABSTRACT Equine arteritis virus (EAV) has the ability to establish persistent infec-
tion in the reproductive tract of the stallion (carrier) and is continuously shed in its
semen. We have recently demonstrated that EAV persists within stromal cells and a
subset of lymphocytes in the stallion accessory sex glands in the presence of a sig-
nificant local inflammatory response. In the present study, we demonstrated that
EAV elicits a mucosal antibody response in the reproductive tract during persistent
infection with homing of plasma cells into accessory sex glands. The EAV-specific im-
munoglobulin isotypes in seminal plasma included IgA, IgG1, IgG3/5, and IgG4/7. In-
terestingly, seminal plasma IgG1 and IgG4/7 possessed virus-neutralizing activity,
while seminal plasma IgA and IgG3/5 did not. However, virus-neutralizing IgG1 and
IgG4/7 in seminal plasma were not effective in preventing viral infectivity. In addi-
tion, the serological response was primarily mediated by virus-specific IgM and IgG1,
while virus-specific serum IgA, IgG3/5, IgG4/7, and IgG6 isotype responses were not
detected. This is the first report characterizing the immunoglobulin isotypes in
equine serum and seminal plasma in response to EAV infection. The findings pre-
sented herein suggest that while a broader immunoglobulin isotype diversity is elic-
ited in seminal plasma, EAV has the ability to persist in the reproductive tract, in
spite of local mucosal antibody and inflammatory responses. This study provides fur-
ther evidence that EAV employs complex immune evasion mechanisms during per-
sistence in the reproductive tract that warrant further investigation.
KEYWORDS equine arteritis virus, equine viral arteritis, EAV, EVA, immunoglobulin
isotype, humoral response, seminal plasma, mucosal immunity, neutralization,
immune evasion, persistent infection, reproductive tract
Equine arteritis virus (EAV) is a small, enveloped virus with a positive-sense, single-stranded RNA genome (ssRNA; the genome is 12,704 bp and contains at least
10 open reading frames [ORFs]) (1–4) and belongs to the family Arteriviridae (genus
Equartevirus), order Nidovirales, a group that includes porcine reproductive and respi-
ratory syndrome virus (PRRSV), simian hemorrhagic fever virus (SHFV), lactate
dehydrogenase-elevating virus of mice (LDV), and the recently recognized wobbly
possum disease virus (WPDV) of free-ranging Australian brushtail possums (Trichosurus
vulpecula) in New Zealand (1, 4–8). EAV is the causative agent of equine viral arteritis
(EVA), a respiratory and reproductive disease of equids (1, 5, 9–11).
While the vast majority of natural infections are inapparent, occasional outbreaks of
EVA occur and are clinically characterized by influenza-like clinical signs in adult horses,
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abortion in pregnant mares, and fatal bronchointerstitial pneumonia or pneumoenteric
syndrome in foals (12). Most importantly, EAV can establish persistent infection in the
reproductive tract of 10 to 70% of infected stallions (carrier state) (13–18). Persistently
infected stallions continuously shed EAV solely in their semen without exhibiting any
clinical signs or a loss of fertility (1, 5, 11–14, 16, 19, 20). The carrier state is testosterone
dependent and can last from several weeks or months (viral shedding for 1 year
postinfection; short-term carriers) to several years or even lifelong (viral shedding
for 1 year postinfection; long-term carriers), despite the development of a strong
neutralizing antibody response in serum (1, 5, 11–15, 20, 21). Recently, it has been
demonstrated that host genetics are implicated in the outcome of infection (i.e., the
short- or long-term carrier state) in the stallion (22, 23). Carrier stallions constitute the
natural reservoir for EAV and, thus, play a key epidemiological role, as they ensure
the maintenance and perpetuation of the virus in equine populations between breed-
ing seasons (1, 11, 12). Moreover, they constitute a source of viral genetic and antigenic
variability that can lead to the emergence of novel variants of the virus (19, 24–27; B.
Nam, Z. Mekuria, M. Carossino, G. Li, Y. Zheng, J. Zhang, R. F. Cook, J. R. Campos, K. M.
Shuck, E. Bailey, P. J. Timoney, and U. B. R. Balasuriya, unpublished data).
The EAV particle consists of a nucleocapsid core and seven envelope proteins. GP5
(20 to 44 kDa) and M (17 kDa) are the major envelope proteins of the virus, and they
form a disulfide-linked heterodimer in the particle. Viral glycoprotein GP5 contains four
major neutralization sites (namely, sites A, B, C, and D) that have been extensively
characterized both genetically and antigenically by the use of neutralizing monoclonal
antibodies (MAbs) (28–31). GP5 and M protein heterodimerization is critical for the
posttranslational modification (glycosylation) and conformational maturation of the
neutralization determinants in GP5 and for the induction of antibody responses (28–
34). Even though considerable variation in the amino acid sequence of the GP5
glycoprotein is observed, there is only one known serotype of EAV, and most field viral
strains are broadly neutralized using high-titer polyclonal equine antisera raised against
the prototype virulent Bucyrus strain (VBS) of EAV (32, 35).
Previous studies have demonstrated that after infection EAV induces both specific
complement-fixing (CF) and virus-neutralizing (VN) antibodies (36, 37), which provide
long-lasting immunity and protection from reinfection with most (if not all) viral strains.
Both CF and VN antibodies develop between 7 and 14 days postinfection (dpi), and
their levels peak at either 2 to 3 weeks or 2 to 4 months postinfection, respectively.
Complement-fixing antibodies decline rapidly, while VN antibodies persist for 3 years or
more (15, 17, 32, 34, 36). Both structural proteins (GP5, M, and N) and nonstructural
proteins (nsp2, nsp4, nsp5, and nsp12) induce humoral immunity (38, 39).
The appearance of serum neutralizing antibodies coincides with the successful
neutralization and clearance of EAV from the bloodstream and all body tissues by
approximately 28 dpi (35). However, EAV persists in the reproductive tract of carrier
stallions regardless of the high titers of neutralizing antibodies present in the serum of
these animals (15, 40). The pathogenesis of persistent EAV infection, including the host
factors associated with the establishment and maintenance of persistent infection, is
not fully comprehended and is under extensive investigation in U. B. R. Balasuriya’s
laboratory. Thus, to better understand the EAV-host interaction in the reproductive
tract and the viral mechanisms of immune evasion at the site of persistent infection,
characterization of the host mucosal antibody response to EAV during persistence is of
utmost importance. We hypothesized that EAV escapes antibody-mediated neutraliza-
tion in the reproductive tract and, consequently, continues to be shed in the semen of
infected stallions. In this study, we characterized the mucosal antibody isotype re-
sponse to EAV during persistent infection and identified the presence of EAV-specific
neutralizing immunoglobulins in seminal plasma. The findings from this study further
demonstrate that EAV employs a complex mechanism of immune evasion during
persistent infection in the reproductive tract, with successful viral escape from systemic
humoral and mucosal antibody responses, as well as local inflammatory responses.
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RESULTS
Clinical outcome and establishment of persistent infection in stallions exper-
imentally infected with EAV. The clinical outcome after intranasal challenge with the
EAV KY84 strain in the group of stallions evaluated in this study has been described in
other studies (40, 41). Briefly, all experimentally infected stallions (n  8) developed
moderate to severe clinical signs of EVA following experimental infection, which lasted
a median of 20 days (interquartile range [IQR]  11.25 days), and no signs of disease
or reproductive dysfunction were observed after clinical recovery. Viral shedding in
semen started at between 3 and 5 dpi, and 5/8 experimentally infected stallions
(stallions L137, L138, L139, L141, and L142) shed EAV in semen for a median of 165 days
(IQR  263.5 days) and were classified as short-term carrier stallions (approximate
duration of shedding, 1 year), while 2/8 stallions (stallions L136 and L140) continued
to shed EAV in their semen for 726 dpi (i.e., long-term carrier stallions’ shedding
duration, 1 year). For behavioral reasons, semen collection from one of the stallions
(stallion L143) was not feasible, and the carrier status could not be determined until the
end of the study. The absence of infective virus, viral antigen, and RNA from tissues
derived from the reproductive tract after euthanasia and the minimal inflammation
observed in the accessory sex glands were indicative that this animal stopped shedding
earlier in the course of the study and was considered to be a short-term carrier stallion
(40).
Characterization of serum neutralizing antibody response during EAV persis-
tent infection in stallions. Neutralizing antibodies in serum were initially detected by
8 dpi in all experimentally infected stallions (n  8), with a median antibody titer of 1:16
(range, 1:8 to 1:32). Significantly higher neutralizing antibody titers were observed by
10 dpi, with a median titer of 1:128 (range, 1:32 to 1:256; P  0.001) (Fig. 1A). Serum
neutralizing antibody titers steadily increased and remained high until the end of the
study (726 dpi) independently of the infection status of the stallion (i.e., long-term or
short-term carrier). The median neutralizing antibody titer by 726 dpi was 1:256 (range,
1:128 to 1:512). The increase in serum neutralizing antibody titers showed a moderate
and significant negative correlation with viremia titers (  0.54), suggesting that the
development of neutralizing antibodies might be associated with the clearance of EAV
from the bloodstream and other body tissues, with the exception of the reproductive
tract (Fig. 1A). Differences in antibody titers between long-term (n  2) and short-term
(n  6) carrier stallions were not observed at any time point (P  0.05) (Fig. 1B).
FIG 1 Neutralizing antibody and viremia titers following experimental EAV infection of stallions (n  8). A negative correlation between the rise in neutralizing
antibody titers and the viremia titers was observed (A), but no differences in neutralizing antibody titers between short-term (n  6) and long-term (n  2)
persistently infected stallions were detected (B).
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Characterization of serological immunoglobulin isotype profile during EAV
persistent infection in stallions. The immunoglobulin profile induced by EAV in the
serum of experimentally infected stallions was characterized using a panel of EAV-
specific capture isotyping enzyme-linked immunosorbent assays (ELISAs) (IgM, IgA,
IgG1, IgG3/5, IgG4/7, and IgG6). The humoral response to EAV was characterized by an
early onset of virus-specific IgM (6 to 8 dpi) (Fig. 2A), which was coincident with
seroconversion, as determined by a virus neutralization test (VNT). Only two out of
eight stallions showed a positive IgM response as early as 6 dpi (stallions L136 and
L143). Fifty percent of the animals had detectable EAV-specific IgM by 8 dpi (stallions
L136, L139, L142, and L143), and 100% (8/8) had a strong response by 10 dpi. The
IgM-mediated response peaked at between 10 and 14 dpi (mean positive/negative
ratio [PNR]  2.95, P  0.05) and rapidly decayed by 28 dpi (mean PNR  1.5) (Fig. 2A)
in both short- and long-term carrier stallions. An isotype switch to EAV-specific IgG1
followed the initial IgM response, with an onset at 10 dpi (mean PNR  5.16) in 5/8
stallions, coincident with a significant rise in neutralizing antibody titers. EAV-specific
IgG1 responses were significantly increased by 14 dpi (P  0.01) (Fig. 2A). Interestingly,
one stallion (stallion L137) showed a very early IgG1 response (6 dpi, PNR  5.3). The
EAV-specific IgG1 response peaked by 21 dpi (mean PNR  24.3) and remained high in
the serum (mean PNR  20, with individual variations in responses) (Fig. 2A) of
experimentally infected stallions. The IgG1-specific response strongly correlated with
the neutralizing antibody titers (  0.62), and no statistically significant differences in
the magnitude of either the IgM or the IgG1 response between short-term (n  2) and
long-term (n  6) carrier stallions were observed (Fig. 3A). Finally, virus-specific IgA,
IgG3/5, IgG4/7, or IgG6 isotype responses were not detected in the serum of experi-
mentally infected stallions during the course of the study (PNRs  2) (Fig. 2A and 3A).
Characterization of seminal antibody responses during EAV persistent infec-
tion in stallions. Detection of EAV-specific seminal antibodies in sequential seminal
plasma samples collected from a group of experimentally infected stallions (n  7) was
performed by capture isotyping ELISAs, as described in Materials and Methods. The
seminal immunoglobulin profile was characterized by several EAV-specific immuno-
globulin isotypes, including IgM, IgA, and IgG, with several subtypes being involved
(IgG1, IgG3/5, and IgG4/7) (Fig. 2B). EAV-specific seminal plasma IgM followed a pattern
similar to that for serum IgM, with a peak of shedding occurring at 11 dpi (mean PNR 
13.86, P  0.0001) (Fig. 2B). Even though 4/7 stallions presented IgM levels above the
baseline level by 30 dpi (mean PNR  3.5), the levels decayed thereafter (Fig. 3B). No
FIG 2 Serological (A) and seminal plasma (B) antibody isotype responses following experimental EAV infection of stallions
(n  8 and n  7, respectively). (A) Serological antibody responses were mediated by an early virus-specific IgM response
and a later onset of virus-specific IgG1. (B) Seminal plasma antibody responses were mediated by several antibody isotypes,
including virus-specific IgA, IgM, IgG1, IgG3/5, and IgG4/7. The mean positive/negative ratios (PNRs) and standard errors
of the means (bars) are represented. The PNR cutoff value for all isotypes is represented by the dashed lines (the PNR cutoff
was 2 for all ELISAs, with the exception of the seminal plasma IgM ELISA, for which the PNR cutoff was 3).
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FIG 3 Serological (A) and seminal plasma (B) antibody isotype responses during short-term (n  6) and long-term (n  2) persistent
infection in stallions following experimental EAV infection. The mean positive/negative ratios (PNRs) and standard errors of the means
(bars) are represented. The PNR cutoff value for all isotypes is represented by the dashed lines (the PNR cutoff was 2 for all ELISAs,
with the exception of the seminal plasma IgM ELISA, for which the PNR cutoff was 3).
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statistically significant differences between short- and long-term carrier stallions were
observed (Fig. 3B). Furthermore, EAV-specific IgA secretion was initially detected in
seminal plasma by 30 dpi (mean PNR  3.6) (Fig. 2B) in 5/7 stallions and peaked by 107
dpi (mean PNR  15.13) (P  0.0001). IgA levels remained high until the conclusion of
the study (726 dpi) (Fig. 2B), and no significant differences between short- and
long-term carrier stallions were observed at any time point (Fig. 3B).
The EAV-specific seminal immunoglobulin profile included the IgG1, IgG3/5, and
IgG4/7 subtypes. The seminal plasma IgG1 profile followed a pattern similar to that
observed for serum IgG1, and IgG1 became detectable in seminal plasma by 11 dpi
(mean PNR  3.9), reaching its peak by 107 dpi (mean PNR  10.23) (P  0.001). The
seminal plasma IgG1 level remained high until the end of the study, and significant
differences in the magnitude of its response were not observed between short- and
long-term carrier stallions (Fig. 3B). The EAV-specific mucosal IgG3/5 and IgG4/7
responses were triggered later in the course of infection. In the case of seminal plasma
IgG3/5, it was detectable by 107 dpi and peaked by 548 dpi (mean PNR  9.21, P 
0.05) (Fig. 2B). Interestingly, long-term carrier stallions presented significantly higher
PNR values for the seminal IgG3/5 response than short-term carrier stallions, specifi-
cally, at 107, 548, and 726 dpi (P  0.01) (Fig. 3B). Seminal plasma IgG3/5 remained
detectable until the end of the study (726 dpi), except in one stallion (stallion L139, a
short-term carrier). Two out of five short-term carrier stallions did not have detectable
IgG3/5 in seminal plasma at any time point (stallions L137 and L138). Seminal plasma
IgG4/7 was detected by 107 dpi (7/7 stallions, P  0.01), and peak concentrations were
observed by 548 dpi (mean PNR  7.5) and remained detectable until 726 dpi (Fig. 2B),
with significantly higher PNR values being seen in long-term carrier stallions than
short-term carrier stallions from 107 dpi until the conclusion of the study (P  0.05) (Fig.
3B). EAV-specific IgG6 subtype responses were not detected in the seminal plasma of
either long- or short-term carrier stallions during the course of the study.
Specificity of seminal immunoglobulin isotypes for EAV major envelope (GP5
and M) and nucleocapsid proteins. Serum and seminal plasma (mucosal) immuno-
globulin specificity was evaluated by Western immunoblotting after sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) separation of viral proteins from
gradient-purified EAV. Serum and seminal plasma anti-EAV IgG1, as well as seminal
plasma anti-EAV IgA and IgG4/7, presented strong binding to viral proteins of 20 to 44
kDa, 17 kDa, and 14 kDa, corresponding to EAV major structural proteins GP5 and M
and the nucleocapsid (N) protein, respectively (Fig. 4). Seminal plasma anti-EAV IgG3/5
was demonstrated to be specific for the viral GP5 glycoprotein and N protein, while its
specificity for the M protein could not be determined (Fig. 4). The faint bands observed
at 30 kDa (GP5) and 14 kDa (N) could be associated with lower concentrations of this
subtype in seminal plasma or a lower affinity to EAV structural proteins.
Neutralizing capacity of virus-specific mucosal antibody isotypes derived from
stallions experimentally infected with EAV. Serum IgG1 and seminal plasma IgA,
IgG1, IgG3/5, and IgG4/7 were purified from pooled serum and seminal plasma samples
collected at 726 dpi to evaluate their ability to neutralize EAV. A modified microneu-
tralization assay demonstrated that anti-EAV IgG1 and IgG4/7 in seminal plasma elicit
virus neutralization under in vitro conditions. The IgG1 and IgG4/7 purified from the
seminal plasma of short- and long-term carrier stallions presented similar neutralization
endpoints (i.e., the difference was 4-fold). The IgG1 neutralization endpoint in seminal
plasma was estimated to be at average of 6 g/ml and 3 g/ml of purified IgG1 for
short- and long-term carrier stallions, respectively, while the IgG4/7 neutralization
endpoint in seminal plasma was estimated to be 2 g/ml of purified IgG4/7 for both
groups. These neutralization endpoints were similar to those determined for purified
serum IgG1 (3 g/ml). In contrast, IgG3/5 and IgA purified from short- and long-term
carrier stallions did not neutralize EAV under in vitro conditions even at concentrations
of 25 g/ml.
Mucosal antibody production in the accessory sex glands during EAV persis-
tent infection in stallions. EAV infection induced an inflammatory response in the
Carossino et al. Clinical and Vaccine Immunology
October 2017 Volume 24 Issue 10 e00215-17 cvi.asm.org 6
reproductive tract of experimentally infected stallions, and an extensive characteriza-
tion of the inflammatory infiltration has been previously described (40). Histological
lesions in the accessory sex glands of experimentally infected stallions that were
actively shedding EAV at the time of euthanasia (n  2 long-term carrier stallions)
included a bilateral, moderate, multifocal lymphoplasmacytic ampullitis (Fig. 5A and B),
while experimentally infected stallions that underwent viral clearance and interrupted
viral shedding by the time of euthanasia presented with minimal, focal, lymphoplas-
macytic ampullitis (n  6; short-term carrier stallions). Even though inflammatory
lesions were infrequent in vesicular glands and the prostate, a mild lymphoplasmacytic
adenitis of the bulbourethral glands with occasional mononuclear cell foci was ob-
served (Fig. 5C and D). Inflammatory lesions in the accessory sex glands of control
(naive) stallions (n  4) frequently ranged from being absent to being present as
minimal and focal lymphoplasmacytic infiltrates, with these lesions showing a signifi-
cantly lower severity and distribution and significantly lower cumulative scores than
those for long-term carrier stallions (P  0.01), while no statistically significant
differences between naive and short-term carrier stallions were observed, as pre-
viously shown (40). In addition, specific immunostaining scores for diverse inflam-
matory cells infiltrating the ampullae were demonstrated to be significantly higher
in long-term carrier stallions than short-term carrier and control stallions (P 
0.0001) (data not shown) (40). Interestingly, the bulbourethral glands were abun-
dantly infiltrated with plasma cells, as observed by hematoxylin and eosin (H&E)
staining and confirmed by specific immunostaining, as described below (Fig. 5 to 7),
including in naive stallions.
Specific immunoglobulin-producing plasma cell populations in the accessory sex
glands of experimentally infected (n  8) and naive (n  4) stallions were analyzed by
immunohistochemistry (IHC). Immunoglobulin-specific plasma cells were identified
throughout the male accessory sex glands and included IgA-positive (IgA), IgG1-
positive (IgG1), IgG3/5-positive (IgG3/5), and IgG4/7-positive (IgG4/7) plasma cells
(Fig. 6 and 7). IgA plasma cells were the most abundant plasma cell type distributed
along the different male accessory sex glands, particularly in the bulbourethral glands
(with scores of 4 in all stallions evaluated, P  0.01) and ampullae (median scores, 3.5
FIG 4 Specificity of serum and seminal plasma immunoglobulin isotypes for EAV major structural (GP5
and M) and nucleocapsid (N) proteins during persistent infection in stallions. Serum IgG1 and seminal
plasma IgG1, IgG4/7, and IgA demonstrated strong reactivity with viral GP5, M, and N, while IgG3/5
presented weak reactivity with viral GP5 and N. Lanes: A, molecular mass markers; B, control equine
arteritis virus GP5-, M-, and N-specific monoclonal/polyclonal antibodies; 1, prechallenge serum IgG1; 2,
serum IgG1 obtained at 726 dpi; 3, prechallenge seminal plasma IgG1; 4, seminal plasma IgG1 obtained
at 726 dpi; 5, prechallenge seminal plasma IgG3/5; 6, seminal plasma IgG3/5 obtained at 726 dpi; 7,
prechallenge seminal plasma IgG4/7; 8, seminal plasma IgG4/7 obtained at 726 dpi; 9, prechallenge
seminal plasma IgA; 10, seminal plasma IgA obtained at 726 dpi. Lanes A and B are representative
controls (molecular mass markers and purified EAV, respectively). The results presented in lanes 1 to 6,
7 and 8, and 9 and 10 were obtained in independent experiments.
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and 2 in long- and short-term carrier stallions, respectively) (Fig. 6 and 7A and B). The
IgA plasma cell distribution was rare to absent in the ampullae of naive stallions
(median score, 0.5), while IgA plasma cells were as abundant in other glands of naive
stallions as in those of infected stallions. Moreover, scattered IgA glandular epithelial
cells were frequently observed in all accessory sex glands (ampullae, vesicular glands,
prostate, and bulbourethral glands) (Fig. 8A and B) and presented intense cytoplasmic,
apical, and/or basolateral staining. Epithelial staining demonstrated the presence of
mucosal, transepithelial IgA transport to the glandular lumen. In addition, homing of
IgG1 plasma cells primarily involved the ampullae of long-term carrier stallions
(median score, 3) and short-term carrier stallions (median score, 1) and the bulboure-
thral gland of short-term carrier stallions (median score, 2) (Fig. 6 and 7C and D), while
their presence was rare in most of the accessory sex glands of naive stallions (median
score, 0.5); the exception was the bulbourethral glands (median score, 2). IgG3/5
plasma cells were broadly distributed in the accessory sex glands of long-term carrier
stallions, while low numbers were detected in tissues from short-term carrier stallions
(Fig. 6 and 7E and F) and rarely in the ampullae, vesicular glands, and prostate from
naive stallions (median scores, 0 to 0.5). Finally, IgG4/7 plasma cells were observed in
FIG 5 Inflammatory infiltration within accessory sex glands of stallions persistently infected with EAV. (A) Lymphoplasmacytic ampullitis. H&E stain.
Magnification, 200. Bar, 100 m. (B) Higher magnification of the inflammatory focus shown in panel A. Inflammatory cells included lymphocytes and plasma
cells (inset) in multifocal aggregates and lymphocytes and plasma cells dispersed in the lamina propria. H&E stain. Magnification, 400. Bar, 50 m. (C)
Lymphoplasmacytic adenitis, bulbourethral gland. H&E stain. Magnification, 200. Bar, 100 m. (D) Higher magnification of the inflammatory cells shown in
panel C. Inflammatory cells included lymphocytes and plasma cells (inset) in occasional foci and lymphocytes and plasma cells, particularly plasma cells,
dispersed within the lamina propria,. H&E stain. Magnification, 400. Bar, 50 m.
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large numbers in the ampullae and bulbourethral glands of long-term carrier stallions,
while they were observed in all accessory sex glands of short-term carrier stallions (Fig.
6 and 7G and H). Naive stallions presented with occasional IgG4/7 plasma cells in
vesicular glands and the prostate (median score, 1), but, interestingly, higher numbers
of these and IgG3/5 plasma cells were observed in the bulbourethral glands. No
statistically significant differences in plasma cell abundance (as determined by IHC
scores) in accessory sex gland tissues, with the exception of the ampullae (see below),
from long-term carrier, short-term carrier, or naive stallions were observed (P  0.05).
Interestingly, occasional IgG1 and IgG4/7 epithelial cells were observed in the
reproductive epithelium (Fig. 8C and D), indicative of IgG subtype transport across the
epithelial lining.
In the case of the stallions that were actively shedding EAV in their semen at the
conclusion of the study (n  2), Ig-secreting (IgA, IgG1, IgG3/5, and IgG4/7)
plasma cells were associated with the lymphoplasmacytic infiltration observed in the
ampullae and bulbourethral glands (Fig. 7). A higher number of Ig-secreting plasma
cells were observed in the ampullae of long-term carrier stallions than in those of the
short-term carrier stallions and naive (control) stallions (P  0.05), which demonstrates
a certain degree of specificity of these effector cells to home within the main site of EAV
persistence in the reproductive tract. Plasma cells in the ampullae and bulbourethral
glands were also identified by transmission electron microscopy (TEM) (data not
shown).
FIG 6 Distribution of immunoglobulin-specific plasma cells within accessory sex glands (gl.) during EAV persistent infection in
stallions. Plasma cells presented a predominant homing to the ampullae and bulbourethral glands in long-term carrier stallions.
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DISCUSSION
In contrast to many viruses, EAV has evolved a complex mechanism that enables its
long-term persistence (carrier state) in the stallion reproductive tract with no associated
tissue damage, sperm abnormalities, or adverse effects on reproductive performance
(13–15). Recently, it has been demonstrated that EAV persistence in the stallion
reproductive tract occurs despite the induction of host systemic immune responses
(e.g., strong neutralizing antibody response) and the induction of local inflammatory
responses at the site of persistence (40). The strategy employed by EAV to successfully
evade host immune surveillance has yet to be determined. Since the carrier stallion
FIG 7 Immunohistochemical identification of plasma cells located in the accessory sex glands of stallions
persistently infected with EAV. Specific immunoglobulin staining is indicated to the left, and the tissue type
is indicated above each column. IgA plasma cells (A and B), IgG1 plasma cells (C and D), IgG3/5 plasma
cells (E and F), and IgG4/7 plasma cells (G and H) in ampullae (A, C, E, G) and bulbourethral glands (B, D,
F, H) are shown. IHC with 3,3=-diaminobenzidine. Magnification, 400. Bars, 50 m.
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plays a pivotal role in the epidemiology of EAV and constitutes the main challenge for
its control and potential eradication (1, 5, 11, 12, 20), it is important to fully understand
the underlying mechanisms involved in the establishment and maintenance of persis-
tent infection in the stallion reproductive tract. Here, we investigated the antibody
responses in short- and long-term persistently infected stallions following experimental
EAV infection with a specific emphasis on the mucosal antibody response to aid in the
understanding of the host immune factors involved in EAV persistence.
There are 11 immunoglobulin isotypes described in horse serum (IgA, IgD, IgE, IgG1
to IgG7, and IgM), and the role of these immunoglobulins during various viral infections
has been the subject of extensive investigation (42–47). This study demonstrated that
shortly after infection EAV induces a strong serum neutralizing antibody response
comprised of a short-lived IgM response and a long-lasting IgG1 response. This re-
sponse correlates with and likely leads to a reduction in the level of viremia and the
clearance of viral infection from all body tissues, with the exception of the accessory sex
glands of carrier stallions (40). Similar to the response observed following West Nile
virus infection (47), the EAV-neutralizing antibody response was primarily mediated by
IgG1 targeting the major viral structural proteins (GP5 and M) and nucleocapsid
proteins, as previously described (38). Although IgG4/7 is the predominant serum IgG
subtype in horses (43) and is involved in other antiviral responses, such as those against
FIG 8 Immunohistochemical identification of immunoglobulin-positive epithelial cells in the accessory sex glands of stallions persistently infected with EAV. (A
and B) IgA-specific epithelial immunostaining in ampulla (A) and vesicular gland (B); (C) IgG1-specific epithelial immunostaining in the vesicular gland; (D)
IgG4/7-specific epithelial immunostaining in the vesicular gland. IHC with 3,3=-diaminobenzidine. Magnification, 400. Bars, 50 m.
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equine herpesvirus 1 (48) or equine influenza virus (49), we were unable to detect
EAV-specific systemic responses mediated by this or other antibody isotypes besides
IgM and IgG1. This is indicative that other immunoglobulin isotypes either do not
contribute to or play a minor role in systemic EAV-specific responses. However, a lack
of detection of these responses may also be related to the diversity of these isotypes
and technical limitations in identifying EAV-specific responses, as explained elsewhere
(47). Most importantly, serum neutralizing antibodies are not effective in clearing
persistent EAV infection in the reproductive tract. Even though the determinant factors
are unknown, the cell types sustaining persistent EAV replication in the reproductive
tract (40), an immunosuppressed tissue microenvironment (40), T lymphocyte dysfunc-
tion at the site of persistence, or even a limited accessibility of serum antibodies to
reproductive tissues are all valid hypotheses that can explain the failure to clear
persistent infection. These studies are in progress in U. B. R. Balasuriya’s laboratory.
A significant finding from this study is that EAV infection induces a specific and
diverse antibody isotype profile in seminal plasma and homing of plasma cells to the
reproductive tract of infected stallions and, most importantly, that the virus has the
ability to escape mucosal antibody responses, in spite of the variety of immunoglobulin
isotypes involved in such a response. This study has demonstrated that, despite the
presence of seminal plasma IgG1 and IgG4/7 with a neutralization capacity similar to
that determined for serum IgG1 and the higher concentrations of IgG4/7 in seminal
fluid derived from long-term persistently infected stallions, EAV continues to be shed in
the semen of these stallions. Multiple factors may be related to the failure to neutralize
EAV in reproductive tract tissues and seminal plasma, including but not limited to the
emergence of novel phenotypic variants of the virus during persistent infection (escape
mutants) (19, 26; Nam et al., unpublished), viral titers higher than the levels of specific
immunoglobulins in seminal plasma available to neutralize the virus, other seminal
plasma components that may interfere with or reduce immunoglobulin avidity and/or
activation of the complement cascade (50–53), or extracellular vesicle (microvesicle)-
mediated shedding of viral particles that allow escape from antibody surveillance,
boosting viral propagation, as proposed for other viruses (54). Even though higher
concentrations of EAV-specific seminal plasma IgG3/5 were observed in long-term
carrier stallions, IgG3/5 seemed to bind to the EAV GP5 glycoprotein weakly and failed
to neutralize EAV under in vitro conditions. Such findings may reflect the lower avidity
of EAV-specific IgG3/5 for EAV proteins, a lack of significant affinity maturation in
response to EAV, or the ability to activate the complement cascade (44). Similarly,
secretory IgA in seminal plasma showed a lack of neutralizing activity, which could be
related to the inability of this isotype to trigger complement activation through the
classical pathway; rather, this isotype requires the mannose-binding lectin activation
pathway instead (55).
In an attempt to identify the source of mucosal antibodies in the reproductive tract,
we evaluated the homing of specific plasma cells to the accessory sex glands of
infected stallions. The diversity in the plasma cell population observed in these tissues
demonstrates the homing of these effector cells and that the local production of
immunoglobulins is likely the source of secreted antibodies in seminal plasma, which
contribute to the mucosal immune system in the reproductive tract. Interestingly,
plasma cells have been proven to constitute another significant cell component of the
inflammatory response previously described in long-term persistently infected stallions
(40), and the persistence of these cells after interruption of viral shedding supports the
fact that short-term carrier stallions maintain EAV-specific immunoglobulins in seminal
plasma after viral clearance. Finally, immunohistochemical studies have also shown the
transcytosis of IgA as well as other immunoglobulins of the IgG class, specifically, IgG1
and IgG4/7, through the reproductive epithelium. While IgA secretion through mucosal
surfaces is associated with a transcytosis mechanism mediated by the polymeric
immunoglobulin receptor (poly-IgR) in polarized epithelial cells (56), IgG secretion
through epithelial surfaces has been associated with a specific Fc receptor in humans,
namely, FcRn (57, 58). It is likely that this receptor is involved in this process, although
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it has not been characterized in the horse thus far. Although the source of IgM in the
seminal plasma of the accessory sex glands could not be determined since tissue
collection was performed after the IgM response had waned, its response pattern was
similar to the serological IgM response and IgM could have potentially gained access to
the seminal plasma via the poly-Ig secretory pathway (56).
In conclusion, the study presented here demonstrates that although EAV induces
both a serological antibody response and a mucosal antibody response in experimen-
tally infected stallions, both responses are unable to clear viral persistence from
reproductive tract tissues of long-term persistently infected stallions. While the persis-
tence of EAV within reproductive tract lymphocytes may guarantee viral escape from
serum neutralizing antibodies, seminal plasma antibody responses overall have been
demonstrated to be only partially neutralizing (i.e., some IgG subtypes). We have also
shown that the antibody isotype dynamics during EAV infection do not predict the
occurrence of long-term EAV persistence in the stallion reproductive tract. This, along
with the results of our previous studies in the area of EAV persistent infection in the
stallion reproductive tract, demonstrates that a complex combination of host factors is
involved in determining persistence or viral clearance from the reproductive tract.
MATERIALS AND METHODS
Cells and viruses. High-passage rabbit kidney 13 (RK-13 [KY]) cells (originally derived from ATCC
CCL-37 cells; American Type Culture Collection) from passage levels 399 to 409 and equine pulmonary
artery endothelial cells (EECs; University of California, Davis, Davis, CA) (59) were maintained as previously
described (40). Tissue culture fluid (TCF) containing the virulent Bucyrus strain (VBS) of EAV (9) was used
to generate antigen for the EAV-capture enzyme-linked immunosorbent assays (ELISAs) and Western
immunoblotting. TCF containing the KY84 strain of EAV (from passage 1 in EECs; University of Kentucky,
Lexington, KY) (37) was used for the experimental infection of stallions. TCF containing the commercial
live-attenuated vaccine strain of EAV (strain MLV; ARVAC vaccine; Zoetis, Kalamazoo, MI) was used for the
reference virus neutralization test (VNT) and modified microneutralization test as described below.
Stallions. A total of eight sexually mature stallions were included in the study. These were
maintained at the Maine Chance Farm, University of Kentucky, Lexington, KY, and before initiation of the
study were confirmed to be seronegative (titer  1:4) for antibodies to EAV according to the World
Organization for Animal Health (OIE) standardized VNT protocol (60) described below. The stallions were
housed in individual stalls in an isolation facility for the duration of the study at the University of
Kentucky in Lexington, KY. After experimental infection and monitoring for 726 dpi (see below), 2/8
stallions were classified as long-term carriers (duration of viral shedding in semen, 1 year), while 5/8
stallions were classified as short-term carriers (duration of viral shedding in semen, approximately 1
year). For the aforementioned reasons, the carrier status of a single stallion (stallion L143) could not be
determined until postmortem examination, and the stallion was classified as a short-term carrier on the
basis of the absence of infectious virus, viral antigen, and viral RNA from reproductive tract tissues
derived from postmortem examination and minimal inflammation. A control group of naive stallions (n 
4) remained unexposed and unvaccinated against EAV.
Animal care and ethics. This study was performed in strict accordance with the recommendations
in the Guide for the Care and Use of Laboratory Animals of the National Research Council (61). The
Institutional Animal Care and Use Committee (IACUC) at the University of Kentucky, Lexington, KY,
approved this protocol (protocol number 2011-0888). Stallions were humanely euthanized by pentobar-
bital overdose following the American Veterinary Medical Association (AVMA) guidelines for the eutha-
nasia of animals, and all efforts were made to minimize suffering.
Experimental infection and clinical sample collection. Eight stallions (stallions L136 to L143) were
intranasally inoculated in October 2011 with the KY84 strain of EAV (3.75  105 PFU per ml of TCF
delivered in 5 ml Eagle’s minimal essential medium [EMEM]) using a fenestrated catheter and monitored
as previously described (40, 41, 62). Serum samples were sequentially collected in Vacutainer serum
tubes (BD, Franklin Lakes, NJ) at 30 (prechallenge), 6, 8, 10, 14, 21, 28, 42, and 726 (preeuthanasia) dpi.
Serum samples were heat inactivated at 56°C for 30 min, aliquoted, and stored at 20°C until tested.
Semen samples were collected using an artificial vagina during the acute phase and after clinical
recovery, specifically, at 30 (prechallenge), 1, 3, 5, 7, 9, 11, 13, 15, 23, 30, 44, 65, 86, 107, 128, 149, 170,
198, 226, 254, 282, 317, 345, 380, 407, 448, 462, 476, 497, 548, 701, and 726 (preeuthanasia) dpi, for the
purpose of monitoring viral persistence. Semen samples were processed as previously described (17, 40).
Seminal plasma samples were subjected to virus isolation and real-time reverse transcription-quantitative
PCR to estimate the viral load and confirm the virus identity, as previously described (40). For immuno-
globulin profiling, seminal plasma samples collected at 30 (prechallenge), 5, 11, 30, 107, 345, 548, and
726 dpi were tested.
Postmortem examination and tissue collection. Stallions were humanely euthanized by pento-
barbital overdose following AVMA guidelines for the euthanasia of animals. Necropsy examination and
tissue collection were performed at 2 years postinfection. For this study, the accessory sex glands
(ampullae, vesicular glands, prostate, and bulbourethral glands) were collected. Tissues were fixed in 10%
neutral buffered formalin for 24 h and paraffin embedded following standard histological procedures.
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Additionally, tissues were fixed in 4% paraformaldehyde and 3.5% glutaraldehyde in 0.1 M Sorensen’s
buffer for 1.5 h and processed for transmission electron microscopy (TEM) examination.
Antibodies. A panel of monoclonal antibodies to equine immunoglobulin isotypes were used for
EAV-capture ELISA, immunohistochemistry (IHC), isotype purification, and Western immunoblotting, as
described below (Table 1) (42, 63–65). In addition, a MAb specific to EAV GP5 (MAb 6D10) (28) was
purified from ascitic fluid (following a conditioning step with ascites conditioning reagent [Thermo Fisher
Scientific, Waltham, MA]) using a Melon gel IgG purification kit (Thermo Fisher Scientific) according to the
manufacturer’s instructions and biotinylated using an EZ-Link sulfo-NHS biotinylation kit (Thermo Fisher
Scientific) following the manufacturer’s recommendations. Biotin incorporation was evaluated by a
4=-hydroxyazobenzene-2-carboxylic acid assay as recommended by the manufacturer, and the specificity
of biotinylated MAb 6D10 was further evaluated by Western immunoblotting and ELISA. Immunohisto-
chemical staining was performed using a Bond Polymer Refine Detection kit (Leica Biosystems, Buffalo
Grove, IL) as described below. In addition, a goat polyclonal antibody specific to equine IgM (SeraCare
Life Sciences, Milford, MA) was used for the dot blot test. Secondary antibodies conjugated to horse-
radish peroxidase (HRP; goat anti-mouse IgG [HL]-HRP and goat anti-rabbit IgG [HL]-HRP [Southern-
Biotech, Birmingham, AL]) were used for Western immunoblotting.
Antigen production for ELISA. The prototype VBS strain of EAV was propagated once in EECs to
prepare high-titer working stocks as previously described (28, 66). Briefly, EECs were plated in triple-
decker flasks and infected with infectious TCF containing the VBS strain of EAV. After a 90 to 100%
cytopathic effect (CPE) was reached, infected flasks were frozen-thawed once (80°C), and cell lysates
were clarified by centrifugation (3,500  g) at 4°C for 15 min and filtered through a 0.45-m-pore-size
filter unit (Nalgene; Thermo Fisher Scientific). Clarified TCF was subsequently ultracentrifuged (Beckman
Coulter, Miami, FL) at 121,600  g through a 20% sucrose cushion in NET buffer (150 mM NaCl, 5 mM
EDTA, 50 mM Tris-HCl, pH 7.5) at 4°C for 4 h to pellet the virus. Partially purified preparations were
resuspended in a minimal volume of 1 phosphate-buffered saline (PBS; pH 7.4; Gibco) and titrated by
plaque assay on EECs, and total protein was quantified using a spectrophotometer (absorbance at 280
nm) (BioTek Synergy H1 multimode microplate reader; BioTek Instruments, Inc., Winooski, VT) and frozen
at 80°C until it was used. Viral stocks contained a viral titer of 1  109 PFU/ml.
Pooled negative serum and seminal plasma samples. A pooled negative serum sample was
prepared by mixing equivalent amounts of individual serum samples from EAV-seronegative stallions
(n  12; stallions L136 to L143 [prechallenge], N105, N121, O103, and O113). Similarly, a pooled negative
seminal plasma sample was prepared from EAV-seronegative stallions (n  11; stallions L136 to L142
[prechallenge], S-6432, S-6435, S-6465, and S-6519). These pooled samples were used as assay controls
in isotyping ELISAs.
Virus neutralization test. Neutralizing antibodies in serum were evaluated by VNT using the
standardized protocol described in the OIE Manual of Diagnostics and Vaccines for Terrestrial Animals (60)
and a virus working suspension containing 100 50% tissue culture infective doses (TCID50) of the
commercial live-attenuated vaccine strain of EAV (strain MLV) per 25 l in 1 EMEM containing 10%
guinea pig complement (Rockland Immunochemicals, Gilbertsville, PA). The use of the MLV strain of EAV
was based on the existence of a single viral serotype broadly neutralized by polyclonal equine antiserum
and on its standardized use for EAV serological testing, as indicated in the OIE Manual of Diagnostic Tests
and Vaccines for Terrestrial Animals (60). The neutralizing antibody titer was recorded as the reciprocal of
the highest serum dilution that provided at least 75% neutralization of the reference virus.
EAV-specific isotyping ELISAs. To determine the EAV-specific immunoglobulin isotype profiles in
serum and seminal plasma, a panel of EAV-capture ELISAs was developed by using the MAbs listed in
Table 1 and as previously reported (47). Briefly, 96-well enzyme immunoassay/radioimmunoassay
polystyrene high-binding plates (Corning) were coated with 100 l/well containing 4 g/ml of the
corresponding MAb (anti-equine immunoglobulins; Table 1) in coating buffer (0.2 M sodium carbonate-
bicarbonate buffer, pH 9.4 [BupH carbonate-bicarbonate buffer packs; Thermo Fisher Scientific]) and
incubated overnight at 4°C. The coated plates were washed 5 times with an ELISA wash buffer (1 PBS
containing 0.05% Tween 20 [Bio-Rad, Hercules, CA]) using a multiwell washer (Nunc-Immuno; Thermo
Fisher Scientific) and blocked with 5% skim milk in 1 PBS containing 0.05% Tween 20 (200 l/well) for
1 h at room temperature. Following a washing step as described above, each serum sample (diluted
TABLE 1 MAbs specific to the equine immunoglobulin isotypes used in this study
Specificity Clone Applicationa Source (reference)
IgM 1-22 ELISA Cornell University (42)
IgM 2B-63 IHC Cornell University (42)
IgA BVS2 ELISA, WB, isotype purification, IHC Cornell University and University
of Kentucky (63)
IgG1 CVS45 ELISA, WB, isotype purification, IHC Cornell University (64)
IgG3/5 586 ELISA, WB, isotype purification Cornell University (65)
IgG3/5 CVS38 IHCb University of Kentucky (64)
IgG4/7 CVS39 ELISA, WB, isotype purification, IHCb Cornell University and University
of Kentucky (64)
IgG6 267 ELISA Cornell University (65)
aELISA, enzyme-linked immunosorbent assay; WB, Western immunoblotting; IHC, immunohistochemistry.
bTissue culture fluid was utilized for IHC.
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1:100 in blocking buffer) or seminal plasma sample (undiluted) was added in quadruplicate (50 l/well),
and the plate was incubated at 37°C for 1 h. The plates were subsequently washed as described above,
and either partially purified EAV VBS (positive capture) or a gradient-purified protein preparation derived
from mock-infected EECs (negative capture) at a concentration of 30 g/ml of protein was added to each
of 2 wells (50 l/well), respectively. The plates were incubated with the respective antigen overnight at
4°C and washed as described above, followed by incubation with a biotinylated EAV anti-GP5 MAb (MAb
6D10, diluted 1:100 in blocking buffer) for 1 h at 37°C (50 l/well). After a washing step, the plates were
subsequently incubated with a streptavidin-HRP conjugate (50 l/well Pierce high-sensitivity
streptavidin-HRP [Thermo Fisher Scientific] diluted 1:4,000 in blocking buffer) for 1 h at 37°C. 3,3=,5,5=-
Tetramethylbenzidine (TMB; 50 l/well; 1 component; SureBlue; KPL, Gaithersburg, MD) was used as the
substrate, and the reaction was allowed to develop for 10 to 15 min for serum samples or 7 min for
seminal plasma samples at room temperature in the dark and stopped by adding 50 l/well of a 0.18 M
sulfuric acid solution. The plates were read at a wavelength of 450 nm using a BioTek Synergy H1
multimode microplate reader (BioTek Instruments, Inc.). A pooled negative serum sample and a seminal
plasma sample were included as negative controls on every plate. Average optical density (OD) values
were calculated after subtraction of the blank for the positive- and negative-capture wells. A positive/
negative ratio (PNR) was then calculated for each sample, as follows: PNR  (mean OD for positive
capture of the test sample/mean OD for positive capture of the pooled negative control sample). A PNR
cutoff value was calculated as follows: PNR cutoff  (mean PNR for prechallenge samples)  2  SD,
where SD is the standard deviation of the PNR for prechallenge samples. A PNR of 2 was considered
a positive response for all ELISAs except the IgM-capture ELISA performed on seminal plasma, which was
determined to have a PNR cutoff value of 3.
Isotype purification from serum and seminal plasma. Serum IgG1 and seminal plasma IgA, IgG1,
IgG3/5, and IgG4/7 from serum and seminal plasma samples (obtained before challenge and at 726 dpi)
pooled from short-term carrier stallions (stallions L137, L138, L139, L141, L142, and L143) and long-term
carrier stallions (stallions L136 and L140) were purified using an affinity column coupled to each MAb to
equine-specific immunoglobulin isotypes (AminoLink Plus Micro immobilization kit [Thermo Fisher
Scientific]). Briefly, 200 l of MAb (1 mg/ml) was coupled to the resin support overnight at 4°C by
end-over-end mixing, as recommended by the manufacturer. After MAb coupling, the remaining active
binding sites on the resin were blocked with a quenching buffer and sodium cyanoborohydride solution,
as instructed by the manufacturer. For affinity purification, 300 l of the sample (undiluted pooled serum
or seminal plasma previously clarified by centrifugation at 3,000  g for 15 min at 4°C) was added onto
the resin and allowed to bind for 2 h at room temperature with end-over-end mixing. The column was
subsequently washed as instructed by the manufacturer, and bound immunoglobulins were eluted two
times using 100 l of elution buffer (pH 2.8). Eluates were immediately neutralized by adding 5 l of 1
M Tris buffer (pH 9.0) per 100 l of eluate, and purified immunoglobulins were quantified by determi-
nation of the OD at 280 nm using a spectrophotometer (NanoDrop 2000 spectrophotometer; Thermo
Fisher Scientific). Eluted immunoglobulins were evaluated by dot blot testing. Briefly, 5 l of each eluate
was dotted onto a nitrocellulose membrane (Bio-Rad) and air dried. The membrane was subsequently
blocked in 5% skim milk in 1 Tris-buffered saline containing 0.05% Tween 20 (TBS-T; pH 7.6) and
incubated with MAbs to equine immunoglobulins (1 g/ml in blocking buffer) overnight at 4°C. After
extensive washing with TBS-T, the dotted membranes were incubated with a secondary antibody (goat
anti-mouse IgG conjugated with HRP diluted 1:5,000 in blocking solution) for 1 h at room temperature
and developed as indicated below (see “Western immunoblotting” below). To verify the specificity of the
eluates, membranes were incubated with goat anti-equine IgM conjugated with HRP (diluted 1:1,000 in
blocking solution) for 1 h at room temperature and subsequently developed as indicated below.
Western immunoblotting. Western immunoblotting was performed to determine the specificity of
the different EAV-specific isotypes in serum and seminal plasma for viral structural proteins. Briefly,
gradient-purified EAV strain VBS (28, 29) was resuspended in 5 Pierce lane marker reducing sample
buffer containing 0.3 M Tris-HCl, 5% SDS, 50% glycerol, and 100 mM dithiothreitol (DTT) (Thermo Fisher
Scientific) and then subjected to denaturing SDS-PAGE on a 12% resolving gel and 4% stacking gel.
Subsequently, viral proteins subjected to PAGE were wet transferred onto a polyvinylidene difluoride
(PVDF) membrane (Bio-Rad) for 1 h at 4°C. Transferred PVDF membranes were briefly washed in TBS-T
and blocked with 5% skim milk in TBS-T overnight at 4°C. Blocked PVDF membranes were briefly rinsed
in TBS-T and loaded onto a miniblotter (20SL; Immunetics, Cambridge, MA). Pooled seminal plasma
samples (obtained before challenge and at 726 dpi) were added undiluted (350 l/lane), while pooled
serum samples (obtained before challenge and at 726 dpi) were diluted 1:20 in blocking buffer.
Membranes were incubated for 2 h at room temperature with gentle rocking, washed 4 times for 5 min
each time with TBS-T, and incubated with MAbs to selected equine immunoglobulin isotypes (diluted to
1 g/ml in blocking buffer) for 1 h at room temperature with gentle rocking. After subsequent washes,
the membranes were incubated with goat anti-mouse IgG (diluted 1:5,000 in blocking buffer) for 1 h at
room temperature and developed using SuperSignal West Pico chemiluminescent substrate (Thermo
Fisher Scientific), as indicated by the manufacturer. The developed membranes were imaged using an
Azure c300 digital imager system (Azure Biosystems, Dublin, CA). In addition, one membrane lane was
probed with an antibody cocktail (1 g/ml each antibody in blocking buffer) specific to the EAV GP5
(MAb 6D10), M (rabbit polyclonal antibody 7888), and N (MAb 3E2) proteins (28–30, 67, 68). A secondary
antibody cocktail containing goat anti-mouse and anti-rabbit IgG (diluted 1:5,000 in blocking buffer) was
then used.
Modified microneutralization test to assess the neutralizing activity of purified serum IgG1 and
purified seminal plasma IgA, IgG1, IgG3/5, and IgG4/7. The neutralizing activity of purified immu-
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noglobulin isotypes derived from serum (IgG1) and seminal plasma (IgA, IgG1, IgG3/5, and IgG4/7) was
evaluated in a modified microneutralization test. Briefly, serial 2-fold dilutions (1:4 to 1:512) of each
purified immunoglobulin preparation were prepared in 10 l of EMEM (Cellgro) supplemented with 10%
ferritin-supplemented calf serum (HyClone Laboratories, Inc.) and added to triplicate wells in a 384-well
plate (Corning). Ten microliters of a working suspension of the commercial live-attenuated vaccine strain
of EAV (strain MLV; ARVAC vaccine; Zoetis) containing 50 TCID50/10 l in EMEM supplemented with 10%
guinea pig complement (Rockland Immunochemicals) was added to each of duplicate wells, and the
plates were incubated for 1 h at 37°C in 5% CO2. The third replicate was used as a cytotoxicity control.
Finally, 40 l of a high-passage-number RK-13 (KY) cell suspension was added to each well, and the
plates were incubated at 37°C in 5% CO2 for 72 h. The neutralizing antibody titer was recorded as the
reciprocal of the highest serum dilution that provided at least 75% neutralization of the reference virus.
Neutralizing antibody titers were subsequently converted into the minimal concentration of specific
isotype immunoglobulin (micrograms per milliliter) necessary for virus neutralization.
Histopathology and TEM. Sections of formalin-fixed paraffin-embedded (FFPE) tissues (5 m) were
stained with hematoxylin and eosin (H&E) following a standard procedure prior to histological evalua-
tion. Tissue sections were scrutinized by an experienced veterinary pathologist who was blind to the
carrier status of the stallions, and a morphological diagnosis was provided. Inflammatory lesions were
scored as previously described by Carossino et al. (40). For TEM, samples were fixed as indicated above,
postfixed in 1% osmium tetroxide (OsO4) for 1.5 h at 4°C, embedded in Eponate12 resin (Ted Pella, Inc.,
Redding, CA), and polymerized for 48 h at 60°C. Ultrathin sections were obtained using a Reichert
Ultracut E ultramicrotome (Leica Biosystems, Buffalo Grove, IL), collected on copper grids, and counter-
stained with 4% uranyl acetate solution and Reynold’s lead citrate. Images were obtained using a Philips
Tecnai BioTwin 12 transmission electron microscope (FEI, Hillsboro, OR).
Immunohistochemistry. Sections of FFPE tissues (5 m) were mounted on positively charged
Superfrost Plus slides (Fisher Scientific, Pittsburgh, PA) and dried overnight at 37°C. For IgA, IgM, IgG1,
IgG3/5, and IgG4/7 immunostaining, deparaffinization was performed as previously described (40).
Heat-induced epitope retrieval (HIER) was performed using a modified citrate-based ready-to-use
solution (pH 6.1; Dako, Carpinteria, CA) at 96°C for 30 min. The slides were allowed to cool for 20 min and
washed three times in 1 PBS. Immunostaining was performed using a Bond Polymer Refine Detection
kit (Leica Biosystems), and tissue sections were counterstained and mounted as previously described (40).
Palatine tonsil sections were used as both positive and negative (without primary antibody incubation)
controls. The cumulative number of immunohistochemistry-positive plasma cells in five high-magnification
(400) fields was quantified, and a score was assigned, as indicated in Table 2.
Statistical analysis. Data distribution, descriptive statistics, plots, and statistical tests were generated
using JMP10 statistical analysis software (SAS, Cary, NC). Normality and equal variances were assessed by
the Shapiro-Wilk and Hartley’s test, respectively. Neutralizing antibody data lacked normality; conse-
quently, nonparametric tests were used for statistical analysis (Kruskal-Wallis test and Wilcoxon signed-
rank test). Analysis of variance (ANOVA) was used to compare ELISA PNRs between short- and long-term
carrier stallions and between data points (days postinfection). For the latter, Dunnett’s test was used for
multiple comparisons using the baseline PNRs (prechallenge) as controls. Data sets that did not comply
with the assumption of equal variance (serum and seminal IgG3/5 and IgG4/7 PNRs between short- and
long-term carrier stallions) were analyzed using the Welch test. Correlation analysis between serum
neutralizing antibody titers and the serum IgG1 PNR, as well as between serum neutralizing antibody and
viremia titers, was performed by Spearman’s rank correlation method. Statistical significance was set at
a P value of 0.05 for all tests performed.
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TABLE 2 Immunohistochemical scoring system used to assess specific immunoglobulin-
producing plasma cell infiltration in the accessory sex glands
Score No. of immunopositive plasma cellsa
0 None
1 5
2 5–40
3 41–80
4 80
aCumulative number of immunopositive plasma cells in five microscopic fields with a total magnification of
400.
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